PSTX News and Press, Poseida Therapeutics Inc. From 08/03/22

Several biotechs involved in gene editing are higher on Wednesday in the aftermath of Roche's ( OTCQX:RHHBY ) blockbuster deal with CAR-T-focused Poseida Therapeutics ( PSTX ) announced earlier today. One of the biggest gainers -- up more than 30% -- is Alaunos The...

Gainers: Kaspien Holdings ( KSPN ) +136% . Heart Test Laboratories ( HSCS ) +92% . Poseida Therapeutics ( PSTX ) +74% . Eargo ( EAR ) +73% . Ping Identity ( PING ) +60% . Applied DNA ( APDN ) +53% . Golden Sun ( ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Poseida Therapeutics (NASDAQ: PSTX ) stock is soaring on Wednesday after the clinical-stage biotechnology company announced a deal with Roche (OTCMKTS: RHHBY ). The agreement with ...

The clinical-stage biotech Poseida Therapeutics ( NASDAQ: PSTX ) announced a broader partnership with Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) to jointly develop allogeneic CAR-T therapies in a deal valued at up to $6B. Extending the pre-market gains, the shares ...

Gainers: Applied DNA Sciences ( APDN ) +93% . Alnylam Pharmaceuticals ALNY +55% . Poseida Therapeutics PSTX +47% . NeuroOne Medical Technologies ( NMTC ) +31% . Sonoma Pharmaceuticals ( SNOA ) +21% . Losers: BridgeBio Pharma B...

The shares of clinical-stage biotech Poseida Therapeutics ( NASDAQ: PSTX ) spiked ~56% in the pre-market Wednesday after the company announced a partnership with Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) to jointly develop allogeneic CAR-T therapies in a deal valued at...

Applied DNA Sciences ( APDN ) +116% . Poseida Therapeutics ( PSTX ) +81% . Ping Identity Holding ( PING ) +60% Non-GAAP EPS of -$0.34 misses by $0.22, revenue of $72.03M misses by $1.27M. Alnylam Pharmaceuticals ( ALNY ) +47% as Phase 3 tr...

Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies PR Newswire Leveraging Poseida's novel approach to cell therapy and Roche's expertise in developing and commercializing ther...

Renowned Geneticist to Chair Poseida Therapeutics Gene Therapy Scientific Advisory Board PR Newswire SAN DIEGO , July 26, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary...

Poseida Therapeutics Announces Publication Highlighting Potential of Cas-CLOVER™ as an Efficient and Robust Gene Editing System for Developing Allogeneic CAR-T Products PR Newswire Publication highlights ability of Cas-CLOVER to perform multiplexed gene editing ...